Mostrando 10 resultados de: 17
Filtros aplicados
Publisher
Frontiers in Aging Neuroscience(2)
Biomedicine and Pharmacotherapy(1)
Cell and Bioscience(1)
Frontiers in Bioscience - Landmark(1)
Frontiers in Pharmacology(1)
Área temáticas
Enfermedades(16)
Farmacología y terapéutica(8)
Fisiología humana(6)
Medicina y salud(6)
Ginecología, obstetricia, pediatría, geriatría(4)
Origen
scopus(17)
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusDexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways
ArticleAbstract: The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a rePalabras claves:Alzheimer's disease, APPswe/PS1dE9, Dexibuprofen, hippocampus, insulin receptor, Memory impairment, Mitochondria, TauAutores:Antoni Camins, Auladell C., Busquets O., Ettcheto M., Folch J., García M.L., Olloquequi J., Pallás M., Pons L., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusCurrent Research Therapeutic Strategies for Alzheimer's Disease Treatment
ReviewAbstract: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed coPalabras claves:Autores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., García M.L., Olloquequi J., Petrov D., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusCurrent advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases
ReviewAbstract: Effective intervention is essential to combat the coming epidemic of neurodegenerative (ND) diseasesPalabras claves:brain disorders, Brain targeting, CNS nanomedicine, neurodegenerative diseases, neurological diseases, Polymeric nanoparticlesAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Lopez-Machado A.L., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopusExtracellular vesicles, the emerging mirrors of brain physiopathology
ArticleAbstract: Extracellular vesicles are secreted by a wide variety of cells, and their primary functions includePalabras claves:Alzheimer’s disease, exosomes, Extracellular vesicles, Glioblastoma, multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative diseases, Parkinson’s DiseaseAutores:Antoni Camins, Bernuz M., Boada M., Cano A., de Antonio E.E., Ettcheto M., Martí M., Pividori M.I., Puerta R., Ruíz A., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusEpigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy
ArticleAbstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. EpigallocatePalabras claves:Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusExosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
ReviewAbstract: Neurodegenerative diseases constitute a group of pathologies whose etiology remains unknown in manyPalabras claves:exosomes, Extracellular vesicles, Nanomedicine, nanotechnology, neurodegenerative diseasesAutores:Antoni Camins, Boada M., Cano A., Ettcheto M., Muñoz-Morales Á., Ruíz A., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDiscovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice
ArticleAbstract: The combination of the scaffolds of the cholinesterase inhibitor huprine Y and the antioxidant capsaPalabras claves:Autores:Andrisano V., Antoni Camins, Bartolini M., Brazzolotto X., Cieslikiewicz-Bouet M., Cisternas P., Colletier J.P., Coquelle N., De Simone A., Ettcheto M., Firuzi O., García M.L., Inestrosa N.C., Jean L., Muñoz-Torrero D., Nachon F., Oliva C.A., Perez B., Pons M., Renard P.Y., Rendina M., Ricchini M., Sanchez-Lopez E., Saso L., Silman I., Viayna E.Fuentes:scopusMasitinib for the treatment of alzheimer's disease
ArticleAbstract: The actual standard treatment for mild-to-moderately severe Alzheimer's disease only attacks its symPalabras claves:Alzheimer's disease, clinical trials, masitinib, mechanism of actionAutores:Antoni Camins, Auladell C., Cano A., Ettcheto M., Folch J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus